United Therapeutics (NASDAQ:UTHR) CEO Sells $1,793,000.00 in Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 4,000 shares of the firm’s stock in a transaction that occurred on Friday, November 7th. The shares were sold at an average price of $448.25, for a total transaction of $1,793,000.00. Following the completion of the sale, the chief executive officer owned 130 shares in the company, valued at approximately $58,272.50. The trade was a 96.85% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

United Therapeutics Stock Performance

Shares of United Therapeutics stock traded down $5.09 during midday trading on Friday, hitting $448.91. 372,027 shares of the company traded hands, compared to its average volume of 595,927. The firm’s fifty day moving average price is $421.07 and its 200-day moving average price is $342.41. The stock has a market cap of $19.33 billion, a price-to-earnings ratio of 17.01, a PEG ratio of 4.96 and a beta of 0.77. United Therapeutics Corporation has a 12 month low of $266.98 and a 12 month high of $479.50.

United Therapeutics (NASDAQ:UTHR) last issued its earnings results on Wednesday, October 29th. The biotechnology company reported $7.16 earnings per share for the quarter, beating analysts’ consensus estimates of $6.89 by $0.27. The firm had revenue of $799.50 million for the quarter, compared to analyst estimates of $812.87 million. United Therapeutics had a net margin of 40.65% and a return on equity of 18.83%. The company’s quarterly revenue was up 6.8% on a year-over-year basis. During the same quarter last year, the business posted $6.39 earnings per share. Equities research analysts forecast that United Therapeutics Corporation will post 24.48 earnings per share for the current year.

Institutional Trading of United Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Concurrent Investment Advisors LLC acquired a new position in shares of United Therapeutics in the 1st quarter worth approximately $227,000. Envestnet Asset Management Inc. lifted its holdings in United Therapeutics by 18.1% in the first quarter. Envestnet Asset Management Inc. now owns 71,909 shares of the biotechnology company’s stock valued at $22,167,000 after buying an additional 11,029 shares during the period. Crossmark Global Holdings Inc. boosted its position in United Therapeutics by 3.5% during the first quarter. Crossmark Global Holdings Inc. now owns 3,645 shares of the biotechnology company’s stock valued at $1,124,000 after acquiring an additional 123 shares during the last quarter. Rehmann Capital Advisory Group bought a new stake in United Therapeutics during the first quarter valued at $562,000. Finally, Alps Advisors Inc. grew its holdings in United Therapeutics by 10.4% during the 1st quarter. Alps Advisors Inc. now owns 1,116 shares of the biotechnology company’s stock worth $344,000 after acquiring an additional 105 shares during the period. Institutional investors and hedge funds own 94.08% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on UTHR. Morgan Stanley set a $447.00 price objective on United Therapeutics in a research report on Wednesday, October 29th. UBS Group boosted their price target on United Therapeutics from $580.00 to $600.00 and gave the stock a “buy” rating in a report on Thursday. Oppenheimer raised their price objective on shares of United Therapeutics from $510.00 to $575.00 and gave the company an “outperform” rating in a report on Friday, September 5th. Wells Fargo & Company lifted their target price on shares of United Therapeutics from $414.00 to $423.00 and gave the stock an “equal weight” rating in a research report on Thursday, October 30th. Finally, HC Wainwright boosted their target price on shares of United Therapeutics from $500.00 to $525.00 and gave the stock a “buy” rating in a report on Thursday, October 30th. Seven analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, United Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $503.90.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.